| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5603929 | FALCON PHARMS | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
Nov, 2014
(9 years ago) | |
| US5653972 | FALCON PHARMS | Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
Nov, 2014
(9 years ago) | |
Diclofenac Sodium is owned by Falcon Pharms.
Diclofenac Sodium contains Diclofenac Sodium.
Diclofenac Sodium has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Diclofenac Sodium are:
- US5603929
- US5653972
Diclofenac Sodium was authorised for market use on 04 May, 1998.
Diclofenac Sodium is available in solution/drops;ophthalmic dosage forms.
Diclofenac Sodium can be used as treating or controlling ocular inflammation which comprises topically administering to affected eye a composition comprising an nsaid, a polymeric quaternary ammonium compound and boric acid.
The generics of Diclofenac Sodium are possible to be released after 16 November, 2014.
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 04 May, 1998
Treatment: Treating or controlling ocular inflammation which comprises topically administering to affected eye a composition comprising an nsaid, a polymeric quaternary ammonium compound and boric acid
Dosage: SOLUTION/DROPS;OPHTHALMIC
DICLOFENAC SODIUM family patents
